All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
PARADIGM-PV: Ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
Bookmark this article
|
Phlebotomy and aspirin are often used to treat patients with low-risk PV; however, data from the phase II Low-PV study (NCT03003325) demonstrated that this intervention may be inadequate. Disease-modifying treatments appear to be beneficial for patients with PV, regardless of risk category. Ropeginterferon alfa-2b (ropeg) is a novel INF-based therapy with favorable dosing schedules, and a higher ropeg starting-dose (250 µg) with simpler dose titrations has demonstrated potent disease-modifying effect in terms of molecular response induction. Flexible dose adjustments and schedule changes with longer intervals (e.g. once every 3–4 weeks after stabilization of treatment response) offer improved convenience for patients, with improved disease outcomes. PARADIGM-PV (NCT06290765) is a randomized, multicenter phase IV study designed to assess the efficacy and safety of ropeg in patients with low- or high-risk PV. Yacoub et al. detail the study rationale, design, and outcome measures in a recent publication in Annals of Hematology. |
| Key learnings |
| Approximately 70 patients with PV will be enrolled. The study period will be 112 weeks, with a 32-week main treatment phase and an 80-week extension treatment phase, plus an additional 4-week safety follow-up phase. |
| The primary goal is to assess the efficacy of ropeg with a higher starting dose (250 µg) and flexible dosing schedules in reducing phlebotomy dependence, while maintaining Hct values in patients with both low- and high-risk PV. |
| The primary endpoint will be the proportion of patients achieving a response at Week 20–32. Secondary endpoints will include CHR, molecular response, symptom improvement, maintenance of median Hct <45% without PD, and safety. |
| The higher starting dose with subsequently reduced-intensity/stringency maintenance therapy aims to rapidly achieve maximal CHRs and molecular responses and minimize neoplastic cells carrying JAK2 mutations in order to suppress disease progression. |
Abbreviations: CHR, complete hematologic response; Hct, hematocrit; INF, interferon; MPN, myeloproliferative neoplasm; PD, progressive disease; PV, polycythemia vera.
- Yacoub A, Abu-Zeinah G, Qin A, et al. PARADIGM-PV: A randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera. Ann Hematol. Online ahead of print. DOI: 10.1007/s00277-025-06185-5
Your opinion matters
14 votes - 60 days left ...
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox